Thorne’s patented chromium complex
- patented chromium formula
- shown to provide the highest tissue levels of chromium*
- available only from Thorne Research
- supports already normal blood glucose levels*
UltraChrome is Thorne’s patented chromium product, consisting of chromium arginate and chromium 4-oxopyridine, 2,6-dicarboxylate. Compared to other chromium compounds, including chromium picolinate, this combination of chromium chelates appears to have the highest bioavailability.*
In an in vitro study testing glucose uptake by adipocytes, chromium 4-oxopyridine, 2,6-dicarboxylate was shown to have the highest tissue levels and biopotency.* Chromium arginate was the most effective at enhancing the action of insulin at the cellular level.*
Chromium is an essential nutrient for human life and is widely distributed in small quantities in food; however, the refining of flour and sugar has depleted chromium levels in many foods. Metabolic stress, strenuous exercise, and pregnancy can all increase chromium needs.* Studies suggest adequate chromium intake supports already normal blood glucose levels, insulin sensitivity, and sperm count.*
One Capsule Contains:
Chromium (as Chromium Chelidamate Arginate)* 500 mcg.
Other Ingredients: Aspartic Acid, Hypromellose (derived from cellulose) capsule, Leucine, Silicon Dioxide.
*Thorne’s trade name for Chromium (4 oxopyridine,2,6-dicarboxylate, arginate) is UltraChrome®. Its use in this product is protected by U.S. Patent No. 5,665,385.
Suggested Use: Take 1 capsule one to two times daily or as recommended by a health-care practitioner.
This product is contraindicated in an individual with a history of hypersensitivity to any of its ingredients.
This product does not contain wheat, gluten, corn, yeast, soy, egg, dairy products, or artificial colors, artificial sweeteners, or artificial flavors. This product also does not contain lactose, palmitic acid, magnesium stearate, or stearic acid.
If pregnant, consult your health-care practitioner before using this product.
There are no known adverse interactions or contraindications at publication date.